When M-TLSs abundance was the same, there was no significant difference in CD8+Ki-67+ cytotoxic T cells within tumor-region M-TLSs between the two treatment groups, whereas the proportions of proliferating and activated CD20+Ki-67+ B cells, CD21+ DCs, and CD4+Ki-67+ Th cells were higher in the NRCI group. The gene discussed is CD8A; the disease is neoplasm.